MARKET

DAR

DAR

Darling
NYSE

Real-time Quotes | Nasdaq Last Sale

64.34
-2.32
-3.48%
After Hours: 64.34 0 0.00% 17:02 01/15 EST
OPEN
65.61
PREV CLOSE
66.66
HIGH
65.83
LOW
63.38
VOLUME
1.27M
TURNOVER
--
52 WEEK HIGH
68.50
52 WEEK LOW
10.25
MARKET CAP
10.43B
P/E (TTM)
21.80
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Now The Time To Put Darling Ingredients (NYSE:DAR) On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Simply Wall St. · 1d ago
Kellogg (K) Focused on Innovations, Expands Raisin Bran line-up
Zacks.com · 3d ago
Will United Natural (UNFI) Sustain Solid Run on High Demand?
Zacks.com · 3d ago
Here's Why Darling Ingredients (DAR) is a Great Momentum Stock to Buy
Does Darling Ingredients (DAR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 12/25/2020 17:00
New Strong Buy Stocks for December 23rd
New Strong Buy Stocks for December 23rd
Zacks · 12/23/2020 15:21
Is DAR A Good Stock To Buy Now?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Insider Monkey · 12/21/2020 03:09
Darling Ingredients' (NYSE:DAR) Wonderful 443% Share Price Increase Shows How Capitalism Can Build Wealth
Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...
Simply Wall St. · 12/20/2020 07:03
Billionaire Ray Dalio Picks Up These 3 Strong Buy Stocks
Sometimes, the experts will tell us what we already know. Ray Dalio, the founder of Bridgewater Associates, has built a legendary reputation in financial circles, for taking his firm from a home business in his two-bedroom apartment to the international hedge fund giant, employing over 1,500 people and managing more than $138 billion in total assets. But when questioned on how he did it, or how today’s investors can survive the ongoing pandemic crisis, his advice can sound downright ordinary.Dalio’s advice for investing during the pandemic can be summed up easily enough. First, he says to diversify the portfolio. Diversification means spreading out the risk, which in turn will reduce your losses should one – or even several – investments turn south. Second, Dalio tells us not to bother trying to ‘time the market.’ Even the pros don’t usually get this right, and Dalio says that simply buying into a stock you like, and holding it long term, is a better strategy then trying to buy in at the right time. The stock market is a risky place to put your money, and Dalio understands that. His tactics for mitigating that risk are age-old – and have arguably brought him great success. Bearing this in mind, we decided to look at Bridgewater's recent activity for inspiration. Running three stocks Dalio's fund picked up during Q3 through TipRanks’ database, we found out that the analyst community is also on board, as each sports a “Strong Buy” consensus rating.Baxter International (BAX)We will start with Baxter International, a healthcare company based outside of Chicago. Baxter produces medical devices and other products for the treatment of acute and chronic conditions, particularly blood, immune, and kidney diseases. The company markets mainly to healthcare professionals and institutions, rather than the open market, and boasts over $11 billion in annual revenue.The company’s revenues through 2020 have been stable, and in-line with historical values. Baxter ended 2019 with a $3 billion quarter; that slipped to $2.72 billion 1Q20, but had risen steadily to $2.97 billion by 3Q20. The company pays out a modest dividend for investors, which at 24.5 cents per common share gives a yield of 1.3%.Dalio’s position in Baxter is a new one for him. His firm bought up 124,701 shares of the stock, a holding that is worth $9.73 million at current prices.5-star analyst Danielle Antalffy, of SVB Leerink, writes of Baxter, “[We] see BAX's underlying fundamentals -- accelerating sales growth, meaningful margin expansion -- as unchanged. One of the most meaningful datapoints in this quarter was 6% peritoneal dialysis patient growth… well ahead of the mid-single-digit long-term growth outlook for the Renal business that the Street is modeling. As the COVID pressures begin to lift, visibility into the long-term growth drivers should improve, and we would expect the shares to move meaningfully higher.”In line with her bullish comments, Antalffy rates BAX shares an Outperform (i.e. Buy), and her $105 price target implies a 34% one-year upside potential. (To watch Antalffy’s track record, click here)Overall, the analyst consensus rating on Baxter is a Strong Buy, based on 12 reviews that include 11 Buys against just a single Hold. The stock is selling for $78, and its $95 average price target suggest it has room for ~22% upside growth in 2021. (See BAX stock analysis on TipRanks)CVS Health Corporation (CVS)The next stock is another healthcare company, but where Baxter, above, markets to the professional side of that sector, CVS aims squarely at the consumer healthcare market. This company is best known as the CVS pharmacy chain, and is a staple of the retail scene. CVS stores offer a range of home healthcare and hygiene products, along with basic groceries, pharmacy services, and some more specialized prescription medical equipment. The company has brought in more than $130 billion in annual revenues for the past three years.CVS’ revenues showed a slight dip this year, during Q2, when economic conditions deteriorated, but quickly rebounded. The sequence of quarterly earnings in 2020, $66.7 billion, $65.3 billion, and $67.1 billion, show a steady sales base, to be expected from a retailer dealing in products mainly deemed essential during the shutdown policies. Q3 EPS came in at $1.66, well ahead of consensus expectations of $1.33.The dividend here is 50 cents per share, and has been held steady at that level for over three years now. The payment annualizes to $2, and gives a yield of 2.7%.Dalio’s Bridgewater bought 320,039 shares of CVS stock last quarter, expanding a test position that the firm already held. The buy boosted the total holding dramatically, to 333,804 shares, which are now worth $24.87 million.Deutsche Bank analyst George Hill notes that CVS looks set for a ‘peaceful transition of power’ when the current CEO, Larry Merlo, steps down next year. "While we believe Ms. Lynch will likely consider executing upon CVS’ vertically integrated care delivery strategy, we do expect her to take a fresh look at the business and have little fear of exploring new directions. We believe Mr. Merlo’s legacy will be having the courage to try to reshape and better utilize the struggling retail pharmacy with the Aetna deal," Hill noted."CVS is in the early innings on delivering against its vision of a vertically integrated healthcare services company with outsized consumer engagement," the analyst concluded.To this end, Hill rates CVS shares as a Buy, and gives them a $101 price target, indicating his confidence in 35% growth potential over the next months. (To watch Hill’s track record, click here)Overall, CVS has 7 recent Buy reviews and 2 Holds, giving the stock a Strong Buy rating from the analyst consensus. The average price target is $83.29, suggesting an 11% upside from the current share price of $74.50. (See CVS stock analysis on TipRanks)Darling Ingredients (DAR)With the last stock, we move from healthcare to the food industry. Darling Ingredients recycles the waste products of the restaurant industry and the animal-processing industry – namely, oils, fats, and grease – and manufactures usable meat and bone meals, yellow grease, and tallow. The company’s products are used in pet foods, animal feeds, bioenergy, and fertilizers. Darling has delivered strong performance through 2020. The company’s quarterly earnings have held between $848 million and $852 million during the corona crisis, while earnings have been shown year-over-year gains in each quarter. The Q3 results included 61 cents EPS on $850 million in top line revenues. DAR stock has been rising steadily since last winter’s market crash, and is up ~77% year-to-date.This is another new holding for Dalio and Bridgewater. During Q3, the fund pulled the trigger on 69,392 shares, which are now worth $3.46 million. Covering the stock for Wolfe Research, 5-star analyst Sam Margolin is impressed by Darling’s combination of cutting-edge renewable fuels and mature feed segments. “We rate DAR Outperform because of its rapid growth in the Renewable Diesel segment (Diamond Green Diesel JV), supported by its feedstock/manufacturing advantage sourced largely from the base business… DAR’s other segments are Food and Feed ingredients, which are relatively mature compared to Fuels. While we do not expect material growth in Food and Feed, we note that margins in the segments have been remarkably steady over recent years…”These comments support Margolin’s Outperform (i.e. Buy) rating, and his $67 price target implies 34% upside growth next year. (To watch Margolin’s track record, click here)Other analysts are on the same page. With 5 Buys and 1 Hold received in the last three months, the word on the Street is that DAR is a Strong Buy. Shares are currently priced at $49.87, and the $58.83 average price target suggests double-digit growth of 18%. (See DAR stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 12/06/2020 16:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DAR. Analyze the recent business situations of Darling through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DAR stock price target is 60.64 with a high estimate of 84.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 455
Institutional Holdings: 169.57M
% Owned: 104.63%
Shares Outstanding: 162.07M
TypeInstitutionsShares
Increased
81
12.59M
New
90
1.13M
Decreased
144
14.57M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Food Processing
0.00%
Food & Tobacco
-0.23%
Key Executives
Chairman/Director/Chief Executive Officer
Randall Stuewe
Chief Financial Officer/Executive Vice President
Brad Phillips
Executive Vice President/Chief Administrative Officer
Jim Long
Executive Vice President/General Counsel/Secretary
John Sterling
Executive Vice President
John Bullock
Executive Vice President
Rick Elrod
Executive Vice President
Jan van der Velden
Executive Vice President
Jos Vervoort
Chief Accounting Officer
Brenda Snell
Lead Director/Independent Director
Charles Macaluso
Director
Dirk Kloosterboer
Independent Director
Charles Adair
Independent Director
Linda Goodspeed
Independent Director
Mary Korby
Independent Director
Gary Mize
Independent Director
Michael Rescoe
Independent Director
Nicole Ringenberg
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DAR
Darling Ingredients Inc. (Darling) is a developer and producer of sustainable natural ingredients from edible and inedible bio-nutrients, creating a range of ingredients and customized specialty solutions for customers in the pharmaceutical, food, pet food, feed, industrial, fuel, bioenergy and fertilizer industries. The Company operates through three segments: Feed Ingredients, Food Ingredients and Fuel Ingredients. The Company collects and transforms all aspects of animal by-product streams into useable and specialty ingredients, such as gelatin, edible fats, feed-grade fats, animal proteins and meals, plasma, pet food ingredients, organic fertilizers, yellow grease, fuel feedstocks, green energy, natural casings and hides. In addition, the Company provides grease trap services to food service establishments, environmental services to food processors and sells restaurant cooking oil delivery and collection equipment.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Darling Ingredients Inc stock information, including NYSE:DAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DAR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DAR stock methods without spending real money on the virtual paper trading platform.